Since its introduction into clinical medicine in the early 1970s, doxorubicin has become an important anti-cancer drug in the treatment of a variety of solid tumours (Blum & Carter. 1974) . However, its clinical uses are limited by cardiomyopathy (Bristow et al.. 1978) and emergence of drug resistance, particularly multidrug resistance (MDR) (Pastan & Gottesman, 1987) . Over the last 20 years. many anthracycline analogues have been synthesised in an attempt to circumvent the cardiotoxicity and drug resistance associated with doxorubicin.
One promising series of anthracycine derivatives is the morpholinyl analogues, which, compared with doxorubicin, appear to be less cardiotoxic (Sikic et al., 1985) and more cytotoxic against multidrug-resistant tumour cells (Streeter et al., 1985; Watanabe et al., 1988) . Methoxymorpholinyl doxorubicin (MMDX) or FCE 23762 is a morpholinyl analogue possessing a methoxymorpholinyl group at the 3' position of the sugar moiety (Figure 1) . MMDX is at least 80 times more potent than doxorubicin against P388 leukaemia in vivo, but only 3-to 4-fold more potent than doxorubicin in vitro (Grandi et al., 1990) . This compound also maintains in vitro and in vivo cytotoxic activity against P388 leukaemia resistant to doxorubicin (Ripamonti et al., 1992) . In this communication, we report that the in vivo potentiation of MMDX is due to conversion of the parent compound, which is a topoisomerase I and II inhibitor, to a metabolite(s) with DNA-alkylating activity.
Materials and methods

Drugs
Doxorubicin hydrochloride was purchased from Adria Laboratories (Columbus, OH, USA) and reconstituted in sodium chloride injection (USP) as a I mM stock solution. Methoxymorpholinyl doxorubicin hydrochloride was a gift from Farmitalia Carlo Erba (Milan, Italy). The drug was initially dissolved in absolute alcohol to a concentration of 0.1 mM followed by subsequent dilutions with culture medium for cytotoxicity assays or appropriate diluent for topoisomerase I and II assays. Cyclosporin A, 50 mg per 10 ml ampoule. was purchased from Sandoz Pharmaceuticals (East Hanover, NJ, USA).
Cell culture
A human uterine sarcoma cell line, MES-SA, its doxorubicinresistant subline that expresses P-glycoprotein, Dx5 (Harker & Sikic, 1985) , and a human ovarian carcinoma cell line, ES-2 (Lau et al., 1989) , were grown as monolayers in McCoy's 5A medium (Irvine Scientific, Santa Ana, CA, USA) supplemented with 2 mM glutamine, 5 iLg ml-' insulin, 7.5% newborn calf serum, 100 U ml-' penicillin and 100 ig ml1' streptomycin (Gibco Laboratories, Grand Island, NY, USA).
Microsomal incubation
Human liver microsomes were prepared, and incubation with MMDX was performed as previously described (Lau et 1989). Brieflv. MMDX. at a concentration of S jim. was incubated for 30 mn with 0.4 mg ml-' human liver microsomes and 0.4 mm NADPH in 2.5 ml of 0.3 M TIns buffer at pH 7.4. For the inhibition study. the incubation mixture was preincubated with 1-5jigml-' cyclosporin A for 20min before MMDX was added. The mixture was centrifuged at 12,000 g for 10 min and the supernatant was filtered through a 0.2 jim filter. The filtrate was used for MTT assay and alkaline elution as described below.
Cviototoxicitv assay
The cytotoxicity of doxorubicin or MMDX was studied using a modified MTT assay (Mosmann. 1983) . The cells were seeded into a 96-well microtitre plate and allowed to attach overnight. The cells were then grown in various concentrations of each drug for 48 h. followed by incubating with 5 mg ml-' 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyl tetrazolium bromide (MTT) (Sigma. St Louis, MO. USA) for 2-3 h. Absorbance of the wells at 570 nm was determined as previously described (Lau et al.. 1989 .4Akaline and neutral elutions DNA single-strand breaks and DNA cross-links were measured by alkaline elution. and DNA double breaks were studied by neutral elution accordinz to a modified method of Kohn et al. (1981) and Lau et al. (1989) (Figure 7) . Doxorubicin or MMDX. 
Alkaline and neutral elutions
The alkaline elution profiles of ES-2 cells exposed to MMDX under various conditions are shown in Figure 8 . Compared with cells exposed to irradiation alone, the elution rate of DNA was higher for cells exposed to MMDX plus radiation, indicating the presence of DNA strand breaks induced by the drug. This strand breakage induced by MMDX is dose dependent and protein associated, as digestion with proteinase K unmasked over 90% of the breaks as illustrated in Figure 9 . It appears that the maximum strand cleavage was reached at a dose of 500 nM.
Compared with doxorubicin, MMDX induced fewer double-strand DNA breaks as measured by neutral elution. At a concentration of 5 gM, 97 rad equivalents of doublestrand breaks were detected with MMDX, whereas 1,113 rad equivalents were detected with doxorubicin (data not shown). This indicates that MMDX, in contrast to doxorubicin, preferentially induced DNA single-strand breakage. After incubation with microsomes and NADPH, MMDX, at doses of 100 and 250 nM, reduced the DNA elution rate, suggesting the formation of DNA cross-links (Figure 8 ). The extent of DNA cross-linking was directly related to the concentrations of the MMDX preincubated with microsomes and NADPH, as illustrated in Figure 10 .
Methoxymorpholinyl doxorubicin is a novel analogue of doxorubicin with three unique biological characteristics distinguishing this compound from doxorubicin. Firstly, in both in vitro and in vivo studies, MMDX is much more potent than doxorubicin even in tumour cells which are resistant to doxorubicin. Secondly, as compared with the topoisomerase IIinhibiting activity of doxorubicin, MMDX is an inhibitor of both topoisomerases I and II. Lastly, MMDX appears to be metabolised by human microsomal enzymes to a DNA crosslinking product with enhanced cytotoxicity.
As For the MES-SA cells, these ratios were 13 and 2.1 respectively. The preferential intracellular uptake of MMDX over that of doxorubicin has also been demonstrated by the direct measurement of intracellular drug concentrations (Grandi et al., 1990) . MMDX is relatively more lipophilic than doxorubicin (Ripamonti et al., 1992 (Streeter et al.. 1986) . have also been reported to be equally cytotoxic against doxorubicinsensitive and -resistant cells. which is also thought to be because of higher intracellular influx and retention of these drugs in the resistant cells (Coley et al., 1993) .
Doxorubicin inhibits topoisomerase II by DNA intercalation and stabilisation of the DNA, topoisomerase II cleavable complex. leading to double-strand DNA cleavage (Tewey et al., 1984) . MX2 also induces DNA double-strand breaks by the same mechanism (Horichi et al., 1990 (Kronbach et al.. 1988 ). The metabolite with alkylating activity has yet to be identified. Our previous study with morpholinyl doxorubicin showed a similar association of metabolic potentiation and alkylating activity, which could be abolished by the antibody and inhibitors of P450 IIIA (Lau et al.. 1989; Lewis et al.. 1992) . Although the active metabolite of morpholinyl doxorubicin has not been identified, analysis of the reaction mixture by high-performance liquid chromatography revealed the presence of a metabolite with a functional group exchangeable with cyanide ion leading to formation of cyanomorpholinyl doxorubicin (Tracy et al.. 1990 ). This doxorubicin analogue has intrinsic alkylating activity without requiring prior metabolic conversion (Scudder et al.. 1988 
